Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer
The Prostate · 2024
DOI: 10.1002/pros.24630 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Mark P Labrecque und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Background
Androgen receptor (AR) pathway inhibition remains the cornerstone for prostate cancer therapies. However, castration‐resistant prostate cancer (CRPC) tumors can resist AR signaling inhibitors through AR amplification and AR splice variants in AR‐positive CRPC (ARPC), and conversion to AR‐null phenotypes, such as double‐negative prostate cancer (DNPC) and small cell or neuroendocrine prostate cancer (SCNPC). We have shown previously that DNPC can bypass AR‐dependence through fibroblast growth factor receptor (FGFR) signaling. However, the role of the FGFR pathway in other CRPC phenotypes has not been elucidated.
Methods
RNA‐Seq analysis was conducted on patient metastases, LuCaP patient‐derived xenograft (PDX) models, and CRPC cell lines. Cell lines (C4‐2B, VCaP, and 22Rv1) and ex vivo LuCaP PDX tumor cells were treated with enzalutamide (ENZA) and FGFR inhibitors (FGFRi) alone or in combination and sensitivity was determined using cell viability assays. In vivo efficacy of FGFRi in ARPC, DNPC, and SCNPC were evaluated using PDX models.
Results
RNA‐Seq analysis of FGFR signaling in metastatic specimens, LuCaP PDX models, and CRPC cell lines revealed significant FGF pathway activation in AR‐low PC (ARLPC), DNPC, and SCNPC tumors. In vitro/ex vivo analysis of erdafitinib and CH5183284 demonstrated robust and moderate growth suppression of ARPC, respectively. In vivo studies using four ARPC PDX models showed that combination ENZA and CH5183284 significantly suppressed tumor growth. Additional in vivo studies using four ARPC PDX models revealed that erdafitinib monotherapy was as effective as ENZA in suppressing tumor growth, and there was limited combination benefit. Furthermore, two of three DNPC models and two of four SCNPC models responded to CH5183284 monotherapy, suggesting FGFRi responses were model dependent. RNA‐Seq and gene set enrichment analysis of end‐of‐study ARPC tumors treated with FGFRi displayed decreased expression of E2F and MYC target genes and suppressed G2M checkpoint genes, whereas end‐of‐study SCNPC tumors had heterogeneous transcriptional responses.
Conclusions
Although FGFRi treatments suppressed tumor growth across CRPC phenotypes, our analyses did not identify a single pathway or biomarker that would identify tumor response to FGFRi. This is very likely due to the array of FGFR1–4 expression and tumor phenotypes present in CRPC. Nevertheless, our data nominate the FGFR pathway as a clinically actionable target that promotes tumor growth in diverse phenotypes of treatment‐refractory metastatic CRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University of Washington School of Medicine, Seattle, Washington, USA.
- Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
- Department of Medicine, University of Washington School of Medicine, Seattle, Washington, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
ORCID-Profile: Mark P Labrecque, W Nathaniel Brennen, John T Isaacs, Eva Corey, Colm Morrissey
Förderung
- NCI NIH HHS
Zitieren
APA
Labrecque, M. P., Brown, L. G., Coleman, I. M., Nguyen, H. M., Dalrymple, S., Brennen, W. N., Isaacs, J. T., Li, D., Lakely, B., DeLucia, D. C., Lee, J. K., Schweizer, M. T., Lin, D. W., Corey, E., Nelson, P. S., & Morrissey, C. (2024). Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer. The Prostate. https://doi.org/10.1002/pros.24630
Vancouver
Labrecque MP, Brown LG, Coleman IM, Nguyen HM, Dalrymple S, Brennen WN, et al. Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer. The Prostate. 2024. doi:10.1002/pros.24630
BibTeX
@article{Labrecque2024,
author = {Labrecque, Mark P and Brown, Lisha G and Coleman, Ilsa M and Nguyen, Holly M and Dalrymple, Susan and Brennen, W Nathaniel and Isaacs, John T and Li, Dapei and Lakely, Bryce and DeLucia, Diana C and Lee, John K and Schweizer, Michael T and Lin, Daniel W and Corey, Eva and Nelson, Peter S and Morrissey, Colm},
title = {Targeting the fibroblast growth factor pathway in molecular subtypes of castration‐resistant prostate cancer},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24630}
}
EUVIMED